

Amferia raises SEK 6.2 million in investment from Almi Invest, Chalmers Ventures and Business Angels for innovative wound care patches that kill antibiotic resistant bacteria.

22 January 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let's Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

Amferia's innovative, anti-infective solution can be used on everything from simple skin ulcers, to chronic wounds and accidents / burns. The WHO predicts that antibiotic-resistant infections could become the leading cause of both illness and death over the next ten years.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warne, Investment Manager at Almi Invest.

Amferia's patented material, an antimicrobial amphiphilic hydrogel, has been developed through several years of research at Chalmers University of Technology and contains molecules inspired by our own immune system. The material instantly kills all bacteria (even antibiotic resistant) by destroying their cell membranes, all without damaging human cells or entering our bloodstream. The product has the form of a wound-care patch but the material will be used in several other med-tech areas, including catheters.

The cost of antibiotic-resistant infections is enormous and corresponds to US \$ 2 billion per year alone and the wound care market currently generates over US \$ 2 billion globally. However, existing alternatives often contain antibiotics that carry the risk of developing resistance or have a heavy metal based antiseptics that can damage human cells and have negative environmental effects.

Dr. David Storek of Chalmers Ventures points out that “this is really a platform material that will become important in so many diverse med-tech products where there is a need to kill bacteria and prevent infections.”



Amferia AB
AZ BioVenturehub c/o Astra Zeneca,
Pepparedsleden 1, SE-431 83 Mölndal
+46 (0) 762 981 238
Org. Nr 559170-1262

<https://amferia.com>

“The investment enables us to increase lab capacity, scale up production and prepare for CE marking of the product. Furthermore, we will also extend the technology into diverse medical products. Our goal is to fight antibiotic resistance. We aim to have the first product on the market within 2-4 years”, says Anand Kumar Rajasekharan, CEO of Amferia.

= = =

Read more at www.amferia.com

For more information, please contact:

Anand Kumar Rajasekharan, Chief Executive Officer, Amferia, +46 762 981238, AZ BioVenturehub c/o Astra Zeneca, Mölndal, Sweden, anandk@amferia.com